Antiplatelet therapy: Personalized medicine for clopidogrel resistance?
The benefits of clopidogrel in the treatment and prevention of coronary artery disease vary among patients. Studies have identified predictive markers of poor response to clopidogrel that might allow risk stratification of patients. are we ready to enter the age of personalized medicine?
Jean-Sébastien
JS
Hulot
Valentin
V
Fuster
D015415:Biomarkers / Q000097:blood; D000077144:Clopidogrel; D004351:Drug Resistance; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011237:Predictive Value of Tests; D018570:Risk Assessment; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine